M42 Secures Prestigious Awards For Diaverum Acquisition, Expanding Global Healthcare Reach

M42, a global tech-enabled health powerhouse, has secured two prestigious awards at the Bonds, Loans & Sukuk Middle East Awards. The company won both the M&A Deal of the Year and the Local Currency Loan Deal of the Year for its strategic acquisition of Diaverum. These accolades highlight M42’s leadership in the healthcare industry and its commitment to advancing global health through innovative financing and strategic expansion.

In April 2023, M42 acquired Diaverum, a leading global renal care service provider from Bridgepoint Group. This acquisition made M42 the largest healthcare company in the Middle East. The deal expanded M42's presence to 26 countries across Europe, Asia, South America, and the Middle East. It also introduced healthcare services and healthtech solutions in new markets while enhancing M42’s renal care offerings in the GCC.

Today, M42 boasts over 20,000 employees and more than 450 facilities. The acquisition stands out due to its speed of execution and strategic alignment. Despite being the company's first debt raised since its establishment in 2022, M42 showed meticulous negotiation and a non-cumbersome security package.

Financial Strategy

The deal's structure strategically aligned repayments with the company's global operating cash flows. This approach minimised currency risk and optimised debt management in line with M42's long-term objectives. James Sibley, Group Chief Financial Officer at M42, stated, "This milestone is a great honour for both the M42 Investment team and the M42 Finance team."

Commitment to Global Health

Sibley added, "The successful execution of this deal demonstrates our dedication to reshaping the future of health through technology and strategic growth. We are proud of this recognition and remain focused on our mission to deliver the highest level of personalised, precise and preventive health solutions globally."

With inputs from WAM